<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery - Chung, C - 2018 | Cochrane Library</title> <meta content="Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery - Chung, C - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011492.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery - Chung, C - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011492.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011492.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery" name="citation_title"/> <meta content="Caroline Chung" name="citation_author"/> <meta content="MD Anderson Cancer Center" name="citation_author_institution"/> <meta content="caroline.chung.md@gmail.com" name="citation_author_email"/> <meta content="Andrew Bryant" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Paul D Brown" name="citation_author"/> <meta content="Mayo Clinic" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD011492.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/07/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011492.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011492.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011492.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [*therapeutic use]; Antipyrine [*analogs &amp; derivatives, therapeutic use]; Bevacizumab [adverse effects, *therapeutic use]; Brain [diagnostic imaging, *radiation effects]; Brain Edema [diagnostic imaging, drug therapy, etiology]; Drug Therapy, Combination; Edaravone; Gadolinium; Non‐Randomized Controlled Trials as Topic; Radiation Injuries [diagnostic imaging, etiology, *therapy]; Radiosurgery [adverse effects]; Radiotherapy [adverse effects]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011492.pub2&amp;doi=10.1002/14651858.CD011492.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="XHP2gG4h";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011492\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011492\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fr","zh_HANS","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011492.pub2",title:"Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery",firstPublishedDate:"Jul 9, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011492.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011492.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011492.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011492.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011492.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011492.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011492.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011492.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011492.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011492.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5477 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011492.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-sec-0046"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-sec-0047"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-sec-0072"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/appendices#CD011492-sec-0110"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/table_n/CD011492StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/table_n/CD011492StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/information#CD011492-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Caroline Chung</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/information#CD011492-cr-0003">Andrew Bryant</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011492.pub2/information#CD011492-cr-0004">Paul D Brown</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/information/en#CD011492-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 July 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011492.pub2">https://doi.org/10.1002/14651858.CD011492.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011492-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011492-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011492-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011492-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011492-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011492-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011492-abs-0001" lang="en"> <section id="CD011492-sec-0001"> <h3 class="title" id="CD011492-sec-0001">Background</h3> <p>Brain radionecrosis (tissue death caused by radiation) can occur following high‐dose radiotherapy to brain tissue and can have a significant impact on a person's quality of life (QoL) and function. The underlying pathophysiological mechanism remains unclear for this condition, which makes establishing effective treatments challenging. </p> </section> <section id="CD011492-sec-0002"> <h3 class="title" id="CD011492-sec-0002">Objectives</h3> <p>To assess the effectiveness of interventions used for the treatment of brain radionecrosis in adults over 18 years old. </p> </section> <section id="CD011492-sec-0003"> <h3 class="title" id="CD011492-sec-0003">Search methods</h3> <p>In October 2017, we searched the Cochrane Register of Controlled Trials (CENTRAL), MEDLINE, Embase and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) for eligible studies. We also searched unpublished data through Physicians Data Query, <a href="http://www.controlled-trials.com/rct" target="_blank">www.controlled‐trials.com/rct</a>, <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>, and <a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a> for ongoing trials and handsearched relevant conference material. </p> </section> <section id="CD011492-sec-0004"> <h3 class="title" id="CD011492-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of any intervention directed to treat brain radionecrosis in adults over 18 years old previously treated with radiation therapy to the brain. We anticipated a limited number of RCTs, so we also planned to include all comparative prospective intervention trials and quasi‐randomised trials of interventions for brain radionecrosis in adults as long as these studies had a comparison group that reflects the standard of care (i.e. placebo or corticosteroids). Selection bias was likely to be an issue in all the included non‐randomised studies therefore results are interpreted with caution. </p> </section> <section id="CD011492-sec-0005"> <h3 class="title" id="CD011492-sec-0005">Data collection and analysis</h3> <p>Two review authors (CC, PB) independently extracted data from selected studies and completed a 'Risk of bias' assessment. For dichotomous outcomes, the odds ratio (OR) for the outcome of interest was reported. For continuous outcomes, treatment effect was reported as mean difference (MD) between treatment arms with 95% confidence intervals (CIs). </p> </section> <section id="CD011492-sec-0006"> <h3 class="title" id="CD011492-sec-0006">Main results</h3> <p>Two RCTs and one prospective non‐randomised study evaluating pharmacological interventions met the inclusion criteria for this review. As each study evaluated a different drug or intervention using different endpoints, a meta‐analysis was not possible. There were no trials of non‐pharmacological interventions that met the inclusion criteria. </p> <p>A very small randomised, double‐blind, placebo‐controlled trial of bevacizumab versus placebo reported that 100% (7/7) of participants on bevacizumab had reduction in brain oedema by at least 25% and reduction in post‐gadolinium enhancement, whereas all those receiving placebo had clinical or radiological worsening or both. This was an encouraging finding but due to the small sample size we did not report a relative effect. The authors also failed to provide adequate details regarding the randomisation and blinding procedures Therefore, the certainty of this evidence is low and a larger RCT adhering to reporting standards is needed. </p> <p>An open‐label RCT demonstrated a greater reduction in brain oedema (T2 hyperintensity) in the edaravone plus corticosteroid group than in the corticosteroid alone group (MD was 3.03 (95% CI 0.14 to 5.92; low‐certainty evidence due to high risk of bias and imprecision); although the result approached borderline significance, there was no evidence of any important difference in the reduction in post‐gadolinium enhancement between arms (MD = 0.47, 95% CI ‐ 0.80 to 1.74; low‐certainty evidence due to high risk of bias and imprecision). </p> <p>In the RCT of bevacizumab versus placebo, all seven participants receiving bevacizumab were reported to have neurological improvement, whereas five of seven participants on placebo had neurological worsening (very low‐certainty evidence due to small sample size and concerns over validity of analyses). While no adverse events were noted with placebo, three severe adverse events were noted with bevacizumab, which included aspiration pneumonia, pulmonary embolus and superior sagittal sinus thrombosis. In the RCT of corticosteroids with or without edaravone, the participants who received the combination treatment were noted to have significantly greater clinical improvement than corticosteroids alone based on LENT/SOMA scale (OR = 2.51, 95% CI 1.26 to 5.01; low‐certainty evidence due to open‐label design). No differences in treatment toxicities were observed between arms. </p> <p>One included prospective non‐randomised study of alpha‐tocopherol (vitamin E) versus no active treatment was found but it did not include any radiological assessment. As only one included study was a double‐blinded randomised controlled trial, the other studies were prone to selection and detection biases. </p> <p>None of the included studies reported quality of life outcomes or adequately reported details about corticosteroid requirements. </p> <p>A limited number of prospective studies were identified but subsequently excluded as these studies had a limited number of participants evaluating different pharmacological interventions using variable endpoints. </p> </section> <section id="CD011492-sec-0007"> <h3 class="title" id="CD011492-sec-0007">Authors' conclusions</h3> <p>There is a lack of good certainty evidence to help quantify the risks and benefits of interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery. In an RCT of 14 patients, bevacizumab showed radiological response which was associated with minimal improvement in cognition or symptom severity. Although it was a randomised trial by design, the small sample size limits the quality of data. A trial of edaravone plus corticosteroids versus corticosteroids alone reported greater reduction in the surrounding oedema with combination treatment but no effect on the enhancing radionecrosis lesion. Due to the open‐label design and wide confidence intervals in the results, the quality of this data was also low. There was no evidence to support any non‐pharmacological interventions for the treatment of radionecrosis. Further prospective randomised studies of pharmacological and non‐pharmacological interventions are needed to generate stronger evidence. Two ongoing RCTs, one evaluating bevacizumab and one evaluating hyperbaric oxygen therapy were identified. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011492-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011492-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011492-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011492-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011492-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011492-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011492-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011492-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011492-abs-0004" lang="en"> <h3>Interventions for the treatment of brain radionecrosis (radiation‐induced damage) after brain radiation treatment </h3> <p><b>Background</b><br/> When brain tissue dies due to a reaction to radiotherapy it is called <i>brain radionecrosis.</i> Brain radionecrosis can cause damage to the patient’s ability function. What this looks like depends where the radionecrosis has happened in the brain and it can impact on a patient’s quality of life. There are currently limited available treatments for brain radionecrosis. Patients are commonly given powerful anti‐inflammatory drugs (called corticosteroids) and some patients may require surgery to remove the area of brain that has radionecrosis. More effective treatments for this condition are needed. </p> <p><b>Study characteristics</b><br/> In October 2017, we searched a list of literature databases and conference proceedings to identify studies that evaluated treatments for brain radionecrosis. A total of three studies were identified that evaluated drugs of which only two were RCTs and one of these RCTs had only 14 participants. No studies evaluating non‐drug treatments were identified. </p> <p><b>Key findings</b><br/> The two drugs compared to corticosteroids alone in this review were bevacizumab (a drug affecting the blood vessels) and edaravone (a powerful antioxidant). </p> <p>A very small‐sized study reported that bevacizumab improved the appearance of the radionecrosis on magnetic resonance imaging (MRI). This was associated with improvement in neurological symptoms than placebo but also with severe side effects. </p> <p>Edaravone in combination with corticosteroids improved the appearance of radionecrosis on MRI; this was associated with improvement in the reported symptoms using the LENT/SOMA scale. However, the patient and treating team were aware of the particular treatment the patient was receiving, so the reported symptoms may have been influenced by this. </p> <p>None of the included studies reported quality of life outcomes or adequately reported details about corticosteroid requirements. </p> <p>Finally a two arm non‐randomised study of vitamin E versus no active treatment based on patient preference reported improvement in learning and memory, but this study did not report any imaging response. The results may have been influenced as patients chose their study treatment thus introducing other potential biases. </p> <p><b>Certainty of the evidence</b><br/> Based on the findings of this review the certainty of the available evidence is low/very low, which limits our ability to help determine the risks and benefits of the evaluated treatments for brain radionecrosis. The studies were at risk of bias due to aspects of their study designs and/or very limited number of participants. There is a great need for higher‐quality evidence with larger multi‐centre randomised control trials of treatments for brain radionecrosis. In our search of the literature for this review, two ongoing RCTs, one evaluating bevacizumab and one evaluating hyperbaric oxygen therapy were identified. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011492-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011492-sec-0105"></div> <h3 class="title" id="CD011492-sec-0106">Implications for practice</h3> <section id="CD011492-sec-0106"> <p>There is limited evidence ranging from low to very low‐certainty for each outcome at present, which makes it difficult to draw firm conclusions on the benefits and risks of interventions for the treatment of radiation necrosis. Based on this review, bevacizumab show promising results of improving radiographic oedema and post‐gadolinium enhancement with associated symptomatic improvement. However, this was based on a very small double‐blinded randomised controlled trial of 14 patients in total, which introduces a high risk of bias due to the small sample size despite the high‐quality trial design. Edaravone in combination with corticosteroids also resulted in greater reduction in radiographic oedema than corticosteroids alone but had no impact on the reduction in the enhancing lesion. Again, greater symptomatic improvement was observed with the addition of edaravone to corticosteroids but this was a secondary endpoint of the study. However due to the open‐labelled randomised study design, there is high risk of selection bias. The final prospective study of pharmacological intervention was a non‐randomised study of vitamin E and although this demonstrated improvement in cognitive function based on a battery of tests administered by blinded observers, this study was at high risk for selection bias and performance bias. </p> <p>Despite a broad search, no non‐pharmacological intervention study was identified meeting the requirements of this review. Therefore, there is currently no prospective evidence to support the use of any non‐pharmacological intervention for the treatment of brain radionecrosis. </p> </section> <h3 class="title" id="CD011492-sec-0107">Implications for research</h3> <section id="CD011492-sec-0107"> <p>There is a great need for further prospective randomised controlled trials (RCTs) in the treatment of brain radionecrosis. This review identified one trial of bevacizumab and steroids versus placebo and steroids for symptomatic brain radionecrosis that was evaluating patient‐reported symptoms using the MD Anderson Symptom Inventory‐Brain Tumor (MDASI‐BT) as the primary endpoint (<a href="./references#CD011492-bbs2-0009" title="Randomized phase II study: corticosteroids plus bevacizumab versus corticosteroids plus placebo (BeSt) for radionecrosis after radiosurgery for brain metastases. Ongoing studyApril 2016. ">A221208</a>), and one prospective trial of hyperbaric oxygen (HBO) therapy for brain radionecrosis following gamma knife radiosurgery (GKS) that was evaluating clinical improvement using the Rankin score as a primary endpoint (<a href="./references#CD011492-bbs2-0010" title="Treatment of adverse radiation effects after gamma knife radiosurgery (GKS) and hyperbaric oxygen therapy (HBO). Ongoing studyMarch 2016. ">NCT02714465</a>). Additional studies evaluating the clinical impact of treatment rather than radiological improvement will provide clinically meaningful evidence. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011492-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011492-sec-0036"></div> <div class="table" id="CD011492-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Bevacizumab compared to placebo for the treatment of brain radionecrosis after radiotherapy or radiosurgery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Bevacizumab compared to placebo for the treatment of brain radionecrosis after radiotherapy or radiosurgery</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain radionecrosis based on clinical and radiological criteria<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> bevacizumab<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Summary</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in oedema (T2 hyperintensity)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very small sample size so results were reported descriptively. At 6 weeks, all seven (100%) participants on bevacizumab had a reduction in brain oedema by at least 25%, whereas 0/7 participants receiving placebo had this reduction. All participants in the placebo arm had clinical and/or radiological progression. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported due to sparse data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in post‐gadolinium enhancement</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very small sample size so results were reported descriptively. Very small sample size so results were reported descriptively. At 6 weeks, all seven (100%) participants on bevacizumab had a reduction in post‐gadolinium enhancement, whereas 0/7 participants receiving placebo had this reduction. All participants in the placebo arm had clinical and/or radiological progression. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported due to sparse data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in neurological/clinical symptoms/severity<br/> <br/> Follow‐up: range 6 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 or 7 who received bevacizumab had stable or reduced clinical symptoms versus only 2 of 7 who received placebo. 5 of 7 patients had worsening neurological symptoms at 3.1 to 8.8 weeks after the first dose of placebo. </p> <p>Since there appeared to be no differences in neurocognitive test results in the trial versus cross‐over bevacizumab treated participant combined, all bevacizumab participants were pooled into one group. While the validity of this is questionable, no significant differences in neurocognitive function changes or symptom severity were observed with bevacizumab treatment compared with placebo in any of the analyses </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported due to sparse data and validity concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No Severe adverse events in 7/7 placebo patients. 3/11 patients who received bevacizumab had severe adverse events (although this overlapped with cross‐over patients). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="2" valign=""> <p>None of the included studies reported quality of life outcomes or adequately reported details about corticosteroid requirements </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corticosteroid requirements</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to small sample size </p> <p><sup>2</sup> Lack of information regarding the randomisation and blinding procedures and overall high risk of bias </p> <p>3 Concerns over validity of analyses</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011492-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Edaravone plus corticosteroids compared to corticosteroids for the treatment of brain radionecrosis after radiotherapy or radiosurgery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Edaravone plus corticosteroids compared to corticosteroids for the treatment of brain radionecrosis after radiotherapy or radiosurgery</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain radionecrosis based on clinical and radiological criteria<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> edaravone + corticosteroids<br/> <b>Comparison:</b> corticosteroids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Summary</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in oedema (T2 hyperintensity)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>At 3 months after completing study treatment, greater reduction in brain oedema (5.08 ± 10.32 cm<sup>2</sup>) was noted in the edaravone + corticosteroid group (edaravone 30 mg orally twice daily for 14 days plus conventional methylprednisolone 500 mg IV x 3 days followed by tapering prednisone orally) than in the corticosteroid alone group (2.05 ± 6.71 cm<sup>2</sup>) although the result approached borderline significance (P = 0.04) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD = 3.03, 95% CI 0.14 to 5.92</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in post‐gadolinium enhancement</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>At 3 months after completing study treatment, there was no evidence of any important difference in the reduction in post‐gadolinium enhancement between arms (1.67 ± 4.69 cm<sup>2</sup>; control group, 1.20 ± 2.71 cm<sup>2</sup>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD = 0.47, 95% CI ‐0.80 to 1.74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in LENT/SOMA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>At 3 months after completing study treatment, participants who received the combination treatment were noted to have significantly greater clinical improvement than corticosteroids alone measured using the Late Effects Normal Tissue Task Force‐Subjective, Objective, Management, Analytic (LENT‐SOMA) scale and defining improvement as a reduction in the LENT‐SOMA scale of &gt; 1. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR = 2.51, 95% CI 1.26 to 5.01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> LOW <sup>1 2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in neurocognitive function</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No differences in treatment toxicities were observed between arms and no severe adverse events were reported. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="2" valign=""> <p>None of the included studies reported quality of life outcomes or adequately reported details about corticosteroid requirements </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corticosteroid requirements</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup> Open‐label trial </p> <p><sup>2</sup> At overall high risk of bias and/or imprecision in estimate </p> <p><sup>3</sup> Inadequate blinding giving high risk of detection bias </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011492-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011492-sec-0037"></div> <section id="CD011492-sec-0038"> <h3 class="title" id="CD011492-sec-0038">Description of the condition</h3> <p>Brain radionecrosis (tissue death caused by radiation) is a complication that may follow radiotherapy to all or part of the brain (<a href="./references#CD011492-bbs2-0012" title="BlonigenB , SteinmetzR , LevinL , LambaM , WarnickR , BrenemanJ . Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. International Journal of Radiation Oncology, Biology, Physics2010;77(4):996‐1001. ">Blonigen 2010</a>; <a href="./references#CD011492-bbs2-0015" title="GiglioP , GilbertM . Cerebral radiation necrosis. Neurologist2003;9(4):180‐8. ">Giglio 2003</a>). It is most commonly observed following high‐dose radiation treatment for primary or secondary brain tumours. But brain radionecrosis can also develop following high‐dose radiotherapy to non‐central nervous system (CNS) tumours in close approximation to brain tissue, such as nasopharyngeal carcinoma. </p> <p>The incidence of symptomatic brain radionecrosis is increasing because of the growing use of stereotactic radiosurgery and administration of higher cumulative doses of radiation during initial therapy and with salvage radiation therapy for primary and secondary malignant brain tumours, as well as head and neck cancers. Sterotactic radiosurgery can be thought of as a minimally invasive form of surgical practice using numerous focused radiation beams, or a highly precise radiation treatment using very few fractions (treatment sessions) of radiation. Following radiosurgery, the risk of radionecrosis has been estimated at about 10% at one year, although the risk may be higher with longer follow‐up or following repeated radiation treatments (<a href="./references#CD011492-bbs2-0012" title="BlonigenB , SteinmetzR , LevinL , LambaM , WarnickR , BrenemanJ . Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. International Journal of Radiation Oncology, Biology, Physics2010;77(4):996‐1001. ">Blonigen 2010</a>; <a href="./references#CD011492-bbs2-0022" title="MayerR , SminiaP . Reirradiation tolerance of the human brain. International Journal of Oncology, Biology, Physics2008;70(5):1350‐60. ">Mayer 2008</a>; <a href="./references#CD011492-bbs2-0030" title="ShawE , ScottC , SouhamiL , DinapoliR , KlineR , LoefflerJ , et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90‐05. International Journal of Radiation Oncology, Biology, Physics2000;47(2):291‐8. ">Shaw 2000</a>). The overall risk of radionecrosis following fractionated radiotherapy to the brain or head and neck area is not well estimated in the current era of intensity modulated radiotherapy (IMRT). However, with more focal radiation delivery techniques, the patterns and distribution of brain radionecrosis appear to be more focal than previously observed (<a href="./references#CD011492-bbs2-0031" title="SuhJH . Stereotactic radiosurgery for the management of brain metastases. New England Journal of Medicine2010;362:1119‐27. ">Suh 2010</a>). </p> <p>To date, brain radionecrosis has largely been a clinical diagnosis based on clinical and radiological presentation. Clinically, patients can present with or develop significant neurological deterioration, functional loss, and in some cases death. Conventional imaging has limited capability to reliably differentiate tumour progression from radionecrosis. Stereotactic biopsy is sometimes used to aid diagnosis, but this approach also fails to have 100% sensitivity or specificity. To avoid the need for invasive surgical procedures for diagnosis, which can be associated with additional risks to the patient, efforts have been invested in improving the capabilities of imaging investigations to confirm a radiological diagnosis. This includes the use of quantitative measures from conventional magnetic resonance imaging (MRI) and use of perfusion and diffusion MRI, MR spectroscopy, and positron emission tomography (PET) imaging. Studies suggest that the best sensitivity and specificity can be achieved by using a combination of these imaging measures to diagnose brain radionecrosis (<a href="./references#CD011492-bbs2-0011" title="BarajasR , ChangJ , SneedP , SegalM , McDermottM , ChaS . Distinguishing recurrent intra‐axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility‐weighted contrast‐enhanced perfusion MR imaging. AJNR American Journal of Neuroradiology2009;30(2):367‐72. ">Barajas 2009</a>; <a href="./references#CD011492-bbs2-0014" title="DequesadaI , QuislingR , YachnisA , FriedmanW . Can standard magnetic resonance imaging reliably distinguish recurrent tumor from radiation necrosis after radiosurgery for brain metastases? A radiographic‐pathological study. Neurosurgery2008;63(5):898‐903. ">Dequesada 2008</a>; <a href="./references#CD011492-bbs2-0019" title="HoefnagelsF , LagerwaardF , SanchezE , HaasbeekC , KnolD , SlotmanB , et al. Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. Journal of Neurology2009;256(6):878‐87. ">Hoefnagels 2009</a>). </p> </section> <section id="CD011492-sec-0039"> <h3 class="title" id="CD011492-sec-0039">Description of the intervention</h3> <p>Initial therapy for symptomatic brain radionecrosis is typically high‐dose corticosteroids (<a href="./references#CD011492-bbs2-0016" title="GonzalezJ , KumarA , ConradC , LevinV . Effect of bevacizumab on radiation necrosis of the brain. International Journal of Radiation Oncology, Biology, Physics2007;67(2):323‐6. ">Gonzalez 2007</a>). If symptoms continue to progress despite the initiation of high‐dose corticosteroids, surgical resection may be considered (<a href="./references#CD011492-bbs2-0023" title="McPhersonC , WarnickR . Results of contemporary surgical management of RN using frameless stereotaxis and intraoperative magnetic resonance imaging. Journal of Neuro‐oncology2004;68:41‐7. ">McPherson 2004</a>). </p> <section id="CD011492-sec-0040"> <h4 class="title">Pharmacological</h4> <p>We defined pharmacological interventions as a drug given by any route at any therapeutic dose with the intention of reducing the clinical and radiological features of brain radionecrosis. Small single‐institution experimental trials and case series have been reported for pharmacological interventions with anticoagulants, vitamin E and pentoxifylline, and antiangiogenic therapy. </p> </section> <section id="CD011492-sec-0041"> <h4 class="title">Non‐pharmacological</h4> <p>We defined non‐pharmacological interventions as any non‐drug intervention applied to reduce the clinical and radiological features of brain radionecrosis. Small single‐institution experimental trials and case series have been reported for non‐pharmacological interventions with hyperbaric oxygen therapy and laser‐induced thermal therapy. </p> </section> </section> <section id="CD011492-sec-0042"> <h3 class="title" id="CD011492-sec-0042">How the intervention might work</h3> <p>Although the underlying pathophysiology of radionecrosis is still unclear, it has been suggested that high‐dose radiation results in disruption of the blood‐brain barrier, which leads to vasogenic oedema (<a href="./references#CD011492-bbs2-0029" title="SchultheissT , KunL , AngK . Radiation response of the central nervous system. International Journal of Radiation Oncology, Biology, Physics1995;31(5):1093‐112. ">Schultheiss 1995</a>). Accumulation of vasogenic oedema can lead to vascular compromise, which can ultimately result in tissue hypoxia (decrease in tissue oxygen levels), which induces release of proteins that stimulate blood vessel growth and leakiness, including vascular endothelial growth factor (VEGF), causing further potentiation of peritumoral vasogenic oedema (swelling around the tumour) (<a href="./references#CD011492-bbs2-0024" title="NordalR , NagyA , PintilieM , WongC . Hypoxia and hypoxia‐inducible factor‐1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clinical Cancer Research2004;10(10):3342‐53. ">Nordal 2004</a>; <a href="./references#CD011492-bbs2-0027" title="PlateelM , DehouckMP . Hypoxia increases the susceptibility to oxidant stress and the permeability of the blood‐brain barrier endothelial cell monolayer. Journal of Neurochemistry1995;65(5):2138‐45. ">Plateel 1995</a>). </p> <section id="CD011492-sec-0043"> <h4 class="title">Pharmacological</h4> <p>Pharmacological interventions have been aimed at stopping and reversing this proposed VEGF‐driven pathological cascade. For instance, corticosteroids reduce the vasogenic oedema and in turn can help prevent vascular compromise and hypoxia, which perpetuate the pathological cascade. The antiangiogenic agent, bevacizumab, is a monoclonal antibody that binds VEGF and has shown promising results in early clinical reports (<a href="./references#CD011492-bbs2-0016" title="GonzalezJ , KumarA , ConradC , LevinV . Effect of bevacizumab on radiation necrosis of the brain. International Journal of Radiation Oncology, Biology, Physics2007;67(2):323‐6. ">Gonzalez 2007</a>; <a href="./references#CD011492-bbs2-0036" title="WongET , HubermanM , LuX , MahadevanA . Bevacizumab reverses cerebral radiation necrosis. Journal of Clinical Oncology2008;26(34):5649‐50. ">Wong 2008</a>). </p> </section> <section id="CD011492-sec-0044"> <h4 class="title">Non‐pharmacological</h4> <p>Non‐pharmacological interventions may also impact this proposed VEGF‐driven pathological cascade. Surgical resection immediately relieves the mass effect that is leading to vascular compromise, which is perpetuating the pathological process (<a href="./references#CD011492-bbs2-0033" title="TruongM , StClairE , DonahueB , RushS , MillerD , FormentiS , et al. Results of surgical resection for progression of brain metastases previously treated by gamma knife radiosurgery. Neurosurgery2006;59(1):86‐97. ">Truong 2006</a>). Hyperbaric oxygen has the potential to reverse tissue hypoxia to directly stop any further hypoxic tissue necrosis and decrease the release of the VEGF that is perpetuating the pathological process (<a href="./references#CD011492-bbs2-0020" title="LeberK , EderH , KovacH , AneggU , PendlG . Treatment of cerebral radionecrosis by hyperbaric oxygen therapy. Stereotactic &amp; Functional Neurosurgery1998;70(Suppl 1):229‐36. ">Leber 1998</a>; <a href="./references#CD011492-bbs2-0025" title="OhguriT , ImadaH . Effect of prophylactic hyperbaric oxygen treatment for radiation‐induced brain injury after stereotactic radiosurgery of brain metastases. International Journal of Radiation Oncology, Biology, Physics2007;67(1):249‐55. ">Ohguri 2007</a>). </p> </section> </section> <section id="CD011492-sec-0045"> <h3 class="title" id="CD011492-sec-0045">Why it is important to do this review</h3> <p>As a result of a lack of information from any larger trials or a systematic review to guide the management of brain radionecrosis, there is significant heterogeneity in the treatment of brain radionecrosis across institutions. This systematic review provides an up‐to‐date evaluation of available scientific information and clinical trial evidence to guide the current management of brain radiation necrosis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011492-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011492-sec-0046"></div> <p><b>Primary outcome</b> </p> <p>To assess the effectiveness of interventions used for the treatment of brain radionecrosis in adults over 18 years old. </p> <p><b>Secondary outcomes</b> </p> <p> <ul id="CD011492-list-0001"> <li> <p>To assess the safety of interventions used for the treatment of brain radionecrosis in adults by evaluating treatment‐related adverse events. </p> </li> <li> <p>To assess the effectiveness of interventions used for the treatment of brain radionecrosis in adults based on clinical improvement based on physician‐reported or patient‐reported symptoms and functional status. </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011492-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011492-sec-0047"></div> <section id="CD011492-sec-0048"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011492-sec-0049"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) of any intervention for the management of brain radionecrosis in adults previously treated with radiation therapy to the brain. Due to the limited number of RCTs, we also included all comparative prospective intervention trials of any intervention for brain radionecrosis in adults. Quasi‐RCTS were eligible for inclusion if identified. For non‐pharmacological interventions, we additionally included one non‐randomised study of any treatment intended for the treatment of brain radionecrosis as long as the studies had an acceptable comparison group (e.g. standard of care therapy such as corticosteroids). An included non‐RCT was prone to the risk of selection bias so it was given little weight in the review and we acknowledge its limitations in the results and discussion. </p> </section> <section id="CD011492-sec-0050"> <h4 class="title">Types of participants</h4> <p>We included studies that evaluated adults over 18 years old previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain radionecrosis based on clinical and radiological criteria. Pathological confirmation was not required, as tissue confirmation is not frequently acquired in clinical practice and often does not provide a definitive diagnosis due to the presence of necrosis and tumour in the pathological specimen. </p> <p>Clinical and radiological diagnosis of brain radionecrosis was defined as "a growing enhancing lesion with associated oedema in the region of prior high‐dose radiation in the presence of low suspicion of active tumour, lack of tumour involvement within the brain (e.g.head and neck cancer), or advanced imaging evidence to suggest absence of active tumour". </p> </section> <section id="CD011492-sec-0051"> <h4 class="title">Types of interventions</h4> <section id="CD011492-sec-0052"> <h5 class="title">Pharmacological interventions</h5> <p>For pharmacological interventions, we investigated the efficacy and effectiveness of any dose of agent given by any route for the purpose of treating brain radionecrosis. Antioxidant agents such as vitamin E and antiangiogenic agents such as bevacizumab were included. To improve the clinical relevance of this review, we included studies that compared the efficacy and effectiveness of these agents against standard clinical care, which typically includes corticosteroid therapy. </p> </section> <section id="CD011492-sec-0053"> <h5 class="title">Non‐pharmacological Interventions</h5> <p>For non‐pharmacological interventions, we included any treatment given with the aim of treating brain radionecrosis to improve symptoms and prevent progression of the process. These treatments were likely to include surgery and hyperbaric oxygen therapy. For these studies, we reported efficacy and effectiveness as well as toxicity. These interventions were considered against outcomes reported for standard care, typically corticosteroid therapy. </p> </section> </section> <section id="CD011492-sec-0054"> <h4 class="title">Types of outcome measures</h4> <section id="CD011492-sec-0055"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome was radiological response, defined as any reduction in contrast‐enhancing lesions or oedema (i.e. T2‐weighted hyperintensity on MRI or hypodensity on computed tomography (CT)). </p> </section> <section id="CD011492-sec-0056"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011492-list-0002"> <li> <p>Clinical improvement, defined as documented physician‐reported or patient‐reported improvement in neurological status, symptoms, or functional status such as neurocognitive function. </p> </li> <li> <p>Corticosteroid requirements, reported as the ability of patients to decrease their corticosteroid dose or to stop corticosteroids completely. </p> </li> <li> <p>Treatment‐related severe adverse events, including death, haemorrhage, haematological toxicity, pulmonary toxicity, cardiac toxicity, gastrointestinal (GI) toxicity, and infection. Mild and moderate adverse events were not considered within this review. </p> </li> <li> <p>Quality of life (QoL), using scales such as the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI‐BT) and the European Organization for Research and Treatment of Cancer core QoL questionnaire (EORTC QLQ‐C30). </p> </li> </ul> </p> <p>We presented 'Summary of findings tables' <a href="./full#CD011492-tbl-0001">summary of findings Table for the main comparison</a>;<a href="./full#CD011492-tbl-0002">summary of findings Table 2</a> reporting the following outcomes listed in order of priority. </p> <p> <ul id="CD011492-list-0003"> <li> <p>Radiological response</p> </li> <li> <p>Treatment‐related severe adverse events</p> </li> <li> <p>QoL</p> </li> <li> <p>Corticosteroid requirements</p> </li> </ul> </p> </section> </section> </section> <section id="CD011492-sec-0057"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011492-sec-0058"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL, 2017, Issue 10, MEDLINE (1946 to October week 1 2017), Embase (1980 to 2017 week 41), and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982 to October 2017). We have listed the MEDLINE, Embase and CENTRAL search strategies in <a href="./appendices#CD011492-sec-0111">Appendix 1</a>, <a href="./appendices#CD011492-sec-0112">Appendix 2</a> and <a href="./appendices#CD011492-sec-0113">Appendix 3</a>. </p> <p>We identified all relevant articles on PubMed, and used the "Related articles" feature to carry out a further search for newly published articles. We applied no language restrictions in our searches. </p> </section> <section id="CD011492-sec-0059"> <h4 class="title">Searching other resources</h4> <section id="CD011492-sec-0060"> <h5 class="title">Unpublished and grey literature</h5> <p>We searched Metaregister, Physicians Data Query, <a href="http://www.controlled-trials.com/rct" target="_blank">www.controlled‐trials.com/rct</a>, <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>, and <a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a> for ongoing trials. </p> <p>If through these searches we identified ongoing trials that have not been published, we contacted the principal investigators to request relevant data. We approached the major co‐operative trial groups active in this area. We searched conference proceedings and abstracts through ZETOC (<a href="http://zetoc.mimas.ac.uk" target="_blank">http://zetoc.mimas.ac.uk</a>). We searched theses and dissertations through WorldCat (<a href="http://firstsearch.oclc.org" target="_blank">http://firstsearch.oclc.org</a>). </p> </section> <section id="CD011492-sec-0061"> <h5 class="title">Handsearching</h5> <p>We handsearched the reference lists of included studies, key textbooks, and previous systematic reviews. We also handsearched journals and conference materials from the past year in the following sources. </p> <p> <ul id="CD011492-list-0004"> <li> <p>Annual Meeting of the European Association of Neuro‐Oncology (EANO)</p> </li> <li> <p>Annual Congress of the European Society for Radiotherapy and Oncology (ESTRO)</p> </li> <li> <p>Annual Meeting of the World Federation of Neuro‐Oncology (WFNO)</p> </li> <li> <p>Annual Meeting of the American Society of Clinical Oncology (ASCO)</p> </li> <li> <p>Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO)</p> </li> <li> <p>Annual Meeting of the American Society of Neuro‐Oncology (SNO)</p> </li> <li> <p>Bienniel Congress of the International Stereotactic Radiosurgery Society (ISRS)</p> </li> <li> <p>Biennial Meeting of the Leksell Gamma Knife Society (LGKS)</p> </li> <li> <p>Annual Meeting of the Multinational Association of Supportive Care in Cancer (MASCC)</p> </li> <li> <p>Other resources</p> </li> </ul> </p> <p>We made efforts for personal communication with authors of relevant trials and experts at major hospitals performing clinical trials to identify further data that may or may not have been published. We included papers in all languages and carried out translations, if necessary. </p> </section> </section> </section> <section id="CD011492-sec-0062"> <h3 class="title" id="CD011492-sec-0062">Data collection and analysis</h3> <section id="CD011492-sec-0063"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to the reference management database, Endnote. All duplicate references were removed, and two review authors (CC, PB) independently examined the remaining references. The review authors were not blinded to study authors or to affiliations of the studies. We excluded studies that clearly did not meet the inclusion criteria and obtained copies of the full text of potentially relevant references. Two review authors (CC, PB) independently assessed the eligibility of retrieved papers. Review authors resolved any disagreements by discussion and documented reasons for exclusion. </p> </section> <section id="CD011492-sec-0064"> <h4 class="title">Data extraction and management</h4> <p>For included trials, data were abstracted as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011492-bbs2-0017" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Chichester: John Wiley &amp; Sons, 2011. ">Higgins 2011</a>). Two review authors (CC, PB) abstracted data onto a data abstraction form designed for the review. </p> <p>This form included the following data.</p> <p> <ul id="CD011492-list-0005"> <li> <p>Article details (author, year of publication, journal citation, country, and language)</p> </li> <li> <p>Intervention (characteristics and duration)</p> </li> <li> <p>Study design and methodology (including inclusion and exclusion criteria, assignment process, and timing of measurements) </p> </li> <li> <p>Population demographics and total number involved; details of the health status of participants, including tumour histology, prior treatment details, and performance status </p> </li> <li> <p>Outcome measures (radiological response, clinical improvement, corticosteroid requirements, QoL, and adverse events) </p> </li> <li> <p>Risk of bias</p> </li> </ul> </p> <p>We collated and entered data into <a href="./references#CD011492-bbs2-0028" title="Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 5 2014</a>. </p> <p>When possible, all data extracted were based on an intention‐to‐treat (ITT) analysis, such that participants were analysed in the groups to which they were assigned. The time points at which outcomes were collected and reported were noted. </p> <p>For dichotomous variables, we recorded the outcome of interest and the number of participants in each treatment arm assessed at available study time points and number who experienced the outcome of interest. </p> <p>For continuous outcomes, we recorded the final value and standard deviation (SD) of the outcome of interest and the number of participants in each treatment arm assessed at the end of follow‐up, and we used these values to estimate the mean difference (MD) between treatment arms and its standard error (SE). We noted time points at which outcomes were collected and reported. </p> </section> <section id="CD011492-sec-0065"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used Cochrane's tool for assessing the risk of bias in included studies (<a href="./references#CD011492-bbs2-0018" title="HigginsJP , AltmanDG . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011a</a>). This included assessment of: </p> <p> <ul id="CD011492-list-0006"> <li> <p>selection bias: random sequence generation and allocation concealment;</p> </li> <li> <p>performance bias: blinding of participants and personnel (patients and treatment providers);</p> </li> <li> <p>detection bias: blinding of outcome assessment;</p> </li> <li> <p>attrition bias: incomplete outcome data (i.e. if at least 80% of patients were assessed for the primary outcome); </p> </li> <li> <p>reporting bias: selective reporting of outcomes; and</p> </li> <li> <p>other possible sources of bias.</p> </li> </ul> </p> <p>We judged all bias criteria and reported them as having low, high, or unclear risk of bias. We classified the risk of bias as unclear when insufficient information was provided, or when there was uncertainty over the potential for bias. All differences in 'Risk of bias' assessment between the two review authors (CC, PB) were resolved by discussion. </p> </section> <section id="CD011492-sec-0066"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011492-sec-0067"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous outcomes (e.g. reduction in lesion volume or not, clinical improvement or not), we recorded for each study the number of participants who experienced the outcome of interest following treatment at an early time point (within four months of treatment) and at last follow‐up. The odds ratio (OR) with 95% confidence interval (CI) for the outcome of interest was reported. </p> </section> <section id="CD011492-sec-0068"> <h5 class="title">Continuous data</h5> <p>For continuous outcomes (e.g. lesion volume, QoL measures), we expressed treatment effect as MD between treatment arms with 95% CIs, when appropriate; we planned to use standardised mean difference (SMD) method if necessary. </p> </section> </section> <section id="CD011492-sec-0069"> <h4 class="title">Unit of analysis issues</h4> <p>Two review authors (CC, PB) reviewed unit of analysis issues according to information provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and resolved differences by discussion (<a href="./references#CD011492-bbs2-0017" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Chichester: John Wiley &amp; Sons, 2011. ">Higgins 2011</a>). These included any reports describing individuals receiving more than one intervention (e.g. the cross‐over trial, simultaneous treatment of methods for each individual) or multiple observations for the same outcome (e.g. repeated measurements, recurring events). </p> </section> <section id="CD011492-sec-0070"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute missing outcome data for any outcome. If data for the primary outcome were missing, we attempted to contact trial authors to request data on outcomes among participants who were assessed. </p> <p>We included details of missing data in the narrative summary and 'Risk of bias' table, alongside an assessment of the extent to which missing data could have altered the results of the review. </p> </section> <section id="CD011492-sec-0071"> <h4 class="title">Data synthesis</h4> <p>As pertinent studies with similar participants, interventions, and outcomes were not identified, we were unable to pool data in meta‐analyses using <a href="./references#CD011492-bbs2-0028" title="Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 5 2014</a> as we had planned. Consequently results of included studies are reported narratively outlining results of single study analyses and it was not necessary to assess heterogeneity, reporting biases (e.g. funnel plots to assess potential for small‐study effects such as publication bias) or conduct subgroup or sensitivity analyses. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011492-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011492-sec-0072"></div> <section id="CD011492-sec-0073"> <h3 class="title">Description of studies</h3> <section id="CD011492-sec-0074"> <h4 class="title">Results of the search</h4> <p>A total of 3488 studies were identified through CENTRAL, MEDLINE and Embase using the outlined search strategy. The search strategy resulted in 1744 publications once duplicates were removed. Additional search strategies did not yield any further prospective studies on the treatment of brain radionecrosis. </p> <p>Filtering through the titles and abstracts of the 1744 publications, which included a number of relevant reports addressing the treatment of brain radionecrosis but only seven articles retrieved in full text were potentially eligible. Of these three studies were included in the narrative synthesis (<a href="#CD011492-fig-0001">Figure 1</a>). We also identified two ongoing trials and a trial awaiting classification (see below). </p> <div class="figure" id="CD011492-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011492-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011492-sec-0075"> <h4 class="title">Included studies</h4> <p>A total of three prospective studies investigating treatment for brain radionecrosis were included: two randomised controlled trials (RCTs) (one double‐blind, placebo‐controlled and the other an open‐label trial), and one non‐randomised study. Detailed information on the studies included in this review are summarised in the <a href="./references#CD011492-sec-0126" title="">Characteristics of included studies</a> section. </p> <section id="CD011492-sec-0076"> <h5 class="title">Pharmacological</h5> <p>Defining pharmacological interventions as a drug given by any route at any therapeutic dose with the intention of reducing the clinical and radiological features of brain radionecrosis, we identified three prospective trials comparing three different agents against a control arm. </p> <p>Two prospective randomised trials of pharmacological interventions were identified. A randomised, double‐blind, placebo‐controlled trial of bevacizumab 7.5 mg/kg every three weeks x two cycles versus placebo every three weeks x two cycles in adults treated with radiotherapy for brain or head and neck neoplasm completed at least ten months prior to study entry, who developed a radiological diagnosis of brain radionecrosis based on magnetic resonance imaging (MRI) criteria. Patients were allowed to be taking corticosteroids prior to study participation, but they were required to be taking a stable dose for at least one week prior to receiving study treatment. The primary endpoint was radiological response, defined as at least a 25% reduction in brain oedema at six weeks of treatment compared with pre‐treatment. Brain oedema was measured as the volume of hyperintensity on T2‐FLAIR MR images (<a href="./references#CD011492-bbs2-0002" title="LevinV , BidautL , HouP , KumarA , WefelJ , BekeleB , et al. Randomized double‐blind placebo‐controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1487‐95. ">Levin 2011</a>). </p> <p>The second randomised trial was an open‐label trial of patients treated with methylprednisolone 500 mg intravenously x three days followed by prednisone orally on a tapering schedule over 30 days, as tolerated, with or without the addition of edaravone 30 mg orally twice daily for 14 days. Eligible patients were adults (&gt; 18 years old) treated with radiotherapy at least six months prior to study enrolment who had radiographic evidence of radionecrosis based on MRI features. This trial also defined response as at least 25% reduction in volume of T2‐hyperintensity and the primary endpoint was evaluated at three months following the start of treatment (<a href="./references#CD011492-bbs2-0003" title="TangY , RongX , HuW , LiG , YangX , YangJ , et al. Effect of edaravone on radiation‐induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial. Journal of Neuro‐oncology 21 August 2014;120(2):441‐7. [DOI: 10.1007/s11060‐014‐1573‐4] ">Tang 2014</a>). </p> <p>One prospective non‐randomised study allowed patients to choose between vitamin E 1000 international units (IU) twice daily for one year or no active treatment. Eligible patients were adults treated with radiotherapy for nasopharyngeal carcinoma with no evidence of recurrence for at least five years who have developed radiological evidence of unilateral or bilateral temporal lobe necrosis without mental impairment. Unlike the two randomised studies, serial imaging was not evaluated in this study. Patients were assessed at baseline and at one year using a battery of in‐house and more widely utilised neuropsychological tests including the Cantonese version of the Mini‐Mental Status Examination (CMMSE), Hong Kong List Learning Test (HKLLT), Visual Reproduction subtest of the Wechsler Memory Scale III (WMS‐III VR), Category Fluency Test (CFT) and computerized Cognitive Flexibility Test (<a href="./references#CD011492-bbs2-0001" title="ChanA , CheungMC , LawSC , ChanJH . Phase II study of alpha‐tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer January 15, 2004;100(2):398‐404. ">Chan 2004</a>). </p> </section> <section id="CD011492-sec-0077"> <h5 class="title">Non‐pharmacological</h5> <p>Defining non‐pharmacological interventions as any non‐drug intervention employed with the aim of reducing the clinical and radiological features of brain radionecrosis, we did not identify any prospective studies meeting the eligibility criteria for this review. </p> </section> <section id="CD011492-sec-0078"> <h5 class="title">Ongoing studies</h5> <p>Two ongoing trials of treatment for brain radiation necrosis were identified. The first study entitled '<i>Adverse radiation effects after Gamma Knife Radio Surgery and Hyperbaric Oxygen Therapy (GKSHBO</i>)' is a single‐arm Italian study evaluating the impact of hyperbaric oxygen therapy (HBO) on clinical improvement and reduction of oedema documented by MRI in patients aged 10 to 75 years with cerebral radiation necrosis following gamma knife radiosurgery (GKS). The study recently opened in March 2016 and the target enrolment is 65 patients. </p> <p>The second study entitled '<i>Corticosteroids plus bevacizumab versus corticosteroids plus placebo (BeSt) for radionecrosis after radiosurgery for brain metastases</i>' is a multi‐centred randomised phase II trial of bevacizumab and steroids versus steroids and placebo in adult patients who are on corticosteroids for symptomatic radionecrosis following radiosurgery for brain metastases. The primary endpoint is an improvement in patient‐reported symptoms measured using the MD Anderson Symptom Inventory‐Brain Tumor (MDASI‐BT). The study recently opened April 2016 and the target enrolment is 130 patients, 65 patients per arm. </p> </section> </section> <section id="CD011492-sec-0079"> <h4 class="title">Excluded studies</h4> <p>We excluded four studies (<a href="./references#CD011492-bbs2-0004" title="FuruseM , NonoguchiN , KuroiwaT , MiyamotoS , ArawakaY , ShinodaJ , et al. A prospective, multicentre, single‐arm clinical trial of bevacizumab for patients wtih surgically untreatable, symptomatic brain radiation necrosis. Neuro‐Oncology PracticeDecember 2016;3(4):272‐80. ">Furuse 2016</a>; <a href="./references#CD011492-bbs2-0005" title="RaoMS , HargreavesEL , KhanAJ , HafftyBG , DanishSF . Magnetic resonance‐guided laser ablation improves local control for postradiosurgery recurrenceand/or radiation necrosis. Neurosurgery2014;74(6):658‐67. ">Rao 2014</a>; <a href="./references#CD011492-bbs2-0006" title="WangY , PanL , ShengX , MaoY , WangE , ZhangN , DaiJ . Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients. European Journal of Medical Research2012;17:25. ">Wang 2012</a>; <a href="./references#CD011492-bbs2-0007" title="YonezawaS , MiwaK , ShinodaJ , NomuraY , AsanoY , NakayamaN , et al. Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis. Journal of Neuro‐oncology 1 May 2014;119(1):101‐9. ">Yonezawa 2014</a>) because they were single arm studies with no comparison arm. </p> <p>Two prospective single‐arm studies of bevacizumab that evaluated nine patients (<a href="./references#CD011492-bbs2-0007" title="YonezawaS , MiwaK , ShinodaJ , NomuraY , AsanoY , NakayamaN , et al. Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis. Journal of Neuro‐oncology 1 May 2014;119(1):101‐9. ">Yonezawa 2014</a>) and 17 patients (<a href="./references#CD011492-bbs2-0006" title="WangY , PanL , ShengX , MaoY , WangE , ZhangN , DaiJ . Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients. European Journal of Medical Research2012;17:25. ">Wang 2012</a>) were excluded due to a lack of a comparison arm that reflects standard care treatment. The study by Yonezawa and colleagues reported a 65% mean reduction in oedema, measured as the hyperintense volume on T2‐FLAIR MR images, and 80% mean reduction in the volume of the enhancing lesion on T1‐weighted MR images, as well as an improvement in KPS in seven of nine patients (77.8%) (<a href="./references#CD011492-bbs2-0007" title="YonezawaS , MiwaK , ShinodaJ , NomuraY , AsanoY , NakayamaN , et al. Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis. Journal of Neuro‐oncology 1 May 2014;119(1):101‐9. ">Yonezawa 2014</a>) Similarly, Wang and colleagues reported 48.8% mean reduction in hyperintense volume on T2‐FLAIR, 54.9% mean reduction in enhancing volume on the gadolinium‐enhanced T1‐weighted MR images and improvement in KPS in 16 of 17 patients (<a href="./references#CD011492-bbs2-0006" title="WangY , PanL , ShengX , MaoY , WangE , ZhangN , DaiJ . Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients. European Journal of Medical Research2012;17:25. ">Wang 2012</a>). </p> <p>One prospective single‐arm study evaluating the effect of laser‐induced thermal therapy in patients with growing enhancing lesions that were previously treated with SRS, who have KPS &gt; 70 but are poor candidates for re‐irradiation was excluded (<a href="./references#CD011492-bbs2-0005" title="RaoMS , HargreavesEL , KhanAJ , HafftyBG , DanishSF . Magnetic resonance‐guided laser ablation improves local control for postradiosurgery recurrenceand/or radiation necrosis. Neurosurgery2014;74(6):658‐67. ">Rao 2014</a>). The other excluded study (<a href="./references#CD011492-bbs2-0004" title="FuruseM , NonoguchiN , KuroiwaT , MiyamotoS , ArawakaY , ShinodaJ , et al. A prospective, multicentre, single‐arm clinical trial of bevacizumab for patients wtih surgically untreatable, symptomatic brain radiation necrosis. Neuro‐Oncology PracticeDecember 2016;3(4):272‐80. ">Furuse 2016</a>) was a single‐arm study of bevacizumab for patients with surgically untreatable, symptomatic brain radionecrosis. </p> </section> </section> <section id="CD011492-sec-0080"> <h3 class="title">Risk of bias in included studies</h3> <p>The studies included in this review were assessed using the Cochrane 'Risk of bias' tool (<a href="./references#CD011492-bbs2-0017" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Chichester: John Wiley &amp; Sons, 2011. ">Higgins 2011</a>). Any discrepancies in the 'Risk of bias' scores between the two review authors (CC, PD) were resolved by discussion. If there was a risk of unclear bias, attempts were made to contact study authors. A summary of the risks of bias is provided in <a href="#CD011492-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD011492-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011492-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011492-sec-0081"> <h4 class="title">Allocation</h4> <p>Two trials were RCTs but as details of the randomisation process for these trials were not available, the risk of allocation bias is unclear (<a href="./references#CD011492-bbs2-0002" title="LevinV , BidautL , HouP , KumarA , WefelJ , BekeleB , et al. Randomized double‐blind placebo‐controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1487‐95. ">Levin 2011</a>, <a href="./references#CD011492-bbs2-0003" title="TangY , RongX , HuW , LiG , YangX , YangJ , et al. Effect of edaravone on radiation‐induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial. Journal of Neuro‐oncology 21 August 2014;120(2):441‐7. [DOI: 10.1007/s11060‐014‐1573‐4] ">Tang 2014</a>). One study at high risk of allocation bias was a pharmacological intervention study that allowed patient choice to the treatment group or control group (<a href="./references#CD011492-bbs2-0001" title="ChanA , CheungMC , LawSC , ChanJH . Phase II study of alpha‐tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer January 15, 2004;100(2):398‐404. ">Chan 2004</a>). </p> </section> <section id="CD011492-sec-0082"> <h4 class="title">Blinding</h4> <p>One of the trials was described as a double‐blinded randomised trial but as the blinding process was not clearly described, the risk of performance or detection bias remains unclear (<a href="./references#CD011492-bbs2-0002" title="LevinV , BidautL , HouP , KumarA , WefelJ , BekeleB , et al. Randomized double‐blind placebo‐controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1487‐95. ">Levin 2011</a>). Similarly, blinding of personnel, participants and outcome assessors was unclear in <a href="./references#CD011492-bbs2-0003" title="TangY , RongX , HuW , LiG , YangX , YangJ , et al. Effect of edaravone on radiation‐induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial. Journal of Neuro‐oncology 21 August 2014;120(2):441‐7. [DOI: 10.1007/s11060‐014‐1573‐4] ">Tang 2014</a>. One trial (<a href="./references#CD011492-bbs2-0001" title="ChanA , CheungMC , LawSC , ChanJH . Phase II study of alpha‐tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer January 15, 2004;100(2):398‐404. ">Chan 2004</a>) was considered at high risk for performance bias because the participants and personnel were not blinded to the intervention and it was also unclear whether or not the outcome assessor was blinded (unclear risk of detection bias). </p> </section> <section id="CD011492-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p>One study was at low risk of attrition bias because all participants had complete follow‐up and were assessed for the primary outcome measure (<a href="./references#CD011492-bbs2-0002" title="LevinV , BidautL , HouP , KumarA , WefelJ , BekeleB , et al. Randomized double‐blind placebo‐controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1487‐95. ">Levin 2011</a>). A second study had a total of 17 participants who withdrew from the study prior to the measurement of the primary outcome and an additional 11 participants lost to follow‐up (<a href="./references#CD011492-bbs2-0003" title="TangY , RongX , HuW , LiG , YangX , YangJ , et al. Effect of edaravone on radiation‐induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial. Journal of Neuro‐oncology 21 August 2014;120(2):441‐7. [DOI: 10.1007/s11060‐014‐1573‐4] ">Tang 2014</a>). However, since this equated to just 18% attrition, the trial was still considered as being at low risk of attrition bias based on our predefined criteria for low risk of attrition of at least 80% assessment of the primary outcome measure. The third study had an unclear risk of attrition bias because the total number of patients at the end of one year and the time point for the primary endpoint assessment, was not clearly stated (<a href="./references#CD011492-bbs2-0001" title="ChanA , CheungMC , LawSC , ChanJH . Phase II study of alpha‐tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer January 15, 2004;100(2):398‐404. ">Chan 2004</a>). </p> </section> <section id="CD011492-sec-0084"> <h4 class="title">Selective reporting</h4> <p>Outcomes were incompletely and/or inadequately reported so selective reporting was adjudged as being at high risk of bias in all three studies. </p> </section> <section id="CD011492-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>There was insufficient information to permit judgement as to whether any other biases may be present in all three studies. <a href="./references#CD011492-bbs2-0001" title="ChanA , CheungMC , LawSC , ChanJH . Phase II study of alpha‐tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer January 15, 2004;100(2):398‐404. ">Chan 2004</a> (n=29) and <a href="./references#CD011492-bbs2-0002" title="LevinV , BidautL , HouP , KumarA , WefelJ , BekeleB , et al. Randomized double‐blind placebo‐controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1487‐95. ">Levin 2011</a> (n=14) were very small studies but this is not a bias as such and it just means the studies were vastly underpowered and is reflected in the confidence in the estimates. If meta‐analyses had been possible then this would have added power and the precision in effect estimates. </p> </section> </section> <section id="CD011492-sec-0086"> <h3 class="title" id="CD011492-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD011492-tbl-0001"><b>Summary of findings for the main comparison</b> Bevacizumab compared to placebo for the treatment of brain radionecrosis after radiotherapy or radiosurgery</a>; <a href="./full#CD011492-tbl-0002"><b>Summary of findings 2</b> Edaravone plus corticosteroids compared to corticosteroids for the treatment of brain radionecrosis after radiotherapy or radiosurgery</a> </p> <p>The study interventions, outcomes and comparisons were not sufficiently similar to pool data. Three pharmacological studies met the inclusion criteria for this review. Due to differences across the three pharmacological studies, including the mechanism of action of the drugs and evaluated outcomes, the results were reviewed separately. No non‐pharmacological studies met the inclusion criteria for this review. </p> <section id="CD011492-sec-0087"> <h4 class="title">Pharmacological outcomes</h4> <section id="CD011492-sec-0088"> <h5 class="title">Bevacizumab versus placebo</h5> <p>A very small and inadequately powered randomised, double‐blind, placebo‐controlled trial (<a href="./references#CD011492-bbs2-0002" title="LevinV , BidautL , HouP , KumarA , WefelJ , BekeleB , et al. Randomized double‐blind placebo‐controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1487‐95. ">Levin 2011</a>) of bevacizumab (7.5 mg/kg every three weeks x two cycles) versus placebo reported that 100% (7/7) of participants on bevacizumab had reduction in brain oedema (T2 hyperintense volume) by at least 25% and reduction in post‐gadolinium enhancement, whereas all those receiving placebo had clinical and/or radiological progression (five participants in placebo arm experienced progressive clinical symptoms while two patients had radiological progression without progressive symptoms). This was an encouraging finding but due to the small sample size we did not report a relative effect. The authors also failed to provide adequate details regarding the randomisation and blinding procedures. Therefore the quality of this evidence is low for these outcomes. </p> <p>All seven participants receiving bevacizumab were reported to have neurological improvement, whereas five of seven participants on placebo had neurological worsening and just two observed an improvement (low‐certainty evidence due to small sample size). Since there appeared to be no differences in neurocognitive test results in the trial versus cross‐over bevacizumab‐treated participants combined, all bevacizumab participants were pooled into one group. While the validity of this is questionable, no significant differences in neurocognitive function changes or symptom severity were observed with bevacizumab treatment compared with placebo in any of the analyses (<a href="./references#CD011492-fig-0003" title="">Analysis 1.1</a>, <a href="./references#CD011492-fig-0004" title="">Analysis 1.2</a>, <a href="./references#CD011492-fig-0005" title="">Analysis 1.3</a>, <a href="./references#CD011492-fig-0006" title="">Analysis 1.4</a>, <a href="./references#CD011492-fig-0007" title="">Analysis 1.5</a>, <a href="./references#CD011492-fig-0008" title="">Analysis 1.6</a>, <a href="./references#CD011492-fig-0010" title="">Analysis 1.8</a>). All seven participants receiving bevacizumab were reported to have neurological improvement, whereas five of seven participants on placebo had neurological worsening (very low‐certainty evidence due to small‐sample size and concerns over validity of the analyses). </p> <p>No adverse events were reported in the placebo arm, although three severe adverse events were noted with bevacizumab which included aspiration pneumonia, pulmonary embolus and superior sagittal sinus thrombosis. </p> </section> <section id="CD011492-sec-0089"> <h5 class="title">Edaravone plus corticosteroids versus corticosteroids alone</h5> <p>An open‐label RCT (<a href="./references#CD011492-bbs2-0003" title="TangY , RongX , HuW , LiG , YangX , YangJ , et al. Effect of edaravone on radiation‐induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial. Journal of Neuro‐oncology 21 August 2014;120(2):441‐7. [DOI: 10.1007/s11060‐014‐1573‐4] ">Tang 2014</a>) demonstrated a greater reduction in brain oedema in the edaravone plus corticosteroid group (edaravone 30 mg orally twice daily for 14 days plus conventional methylprednisolone 500 mg intravenously x three days followed by tapering prednisone orally) than in the corticosteroid alone group (mean difference (MD) was 3.03 (95%CI 0.14 to 5.92), although the result approached borderline significance (P = 0.04) (<a href="./references#CD011492-fig-0011" title="">Analysis 2.1</a>). There was no evidence of any important difference in the reduction in post‐gadolinium enhancement between arms (MD = 0.47, 95% CI ‐0.80 to 1.74; low‐certainty evidence due to high risk of bias and imprecision) (<a href="./references#CD011492-fig-0012" title="">Analysis 2.2</a>). </p> <p>In the RCT of corticosteroids with or without edaravone, the participants who received the combination treatment were noted to have significantly greater clinical improvement than corticosteroids alone measured using the Late Effects Normal Tissue Task Force‐Subjective, Objective, Management, Analytic (LENT‐SOMA) scale (OR = 2.51, 95%CI 1.26 to 5.01; low‐certainty evidence due to the open‐label design) (<a href="./references#CD011492-fig-0013" title="">Analysis 2.3</a>). No differences in treatment toxicities were observed between arms and no severe adverse events were reported. </p> </section> <section id="CD011492-sec-0090"> <h5 class="title">Vitamin E versus no active treatment</h5> <p>The prospective non‐randomised study (<a href="./references#CD011492-bbs2-0001" title="ChanA , CheungMC , LawSC , ChanJH . Phase II study of alpha‐tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer January 15, 2004;100(2):398‐404. ">Chan 2004</a>) of Vitamin E 1000 IU twice daily for one year versus no active treatment focused on neurocognitive evaluation without reported serial imaging evaluation. Evaluating cognitive function in patients at baseline and after one year of treatment, a 5.3% improvement in global cognitive function on CMMSE was seen in patients who received vitamin E compared with no improvement in the control group (P = 0.007). Assessment of verbal learning using Hong Kong List Learning Test (HKLLT) demonstrated that the treatment group had a 27.2% improvement at one year versus no improvement in the control group. Similarly, improvements were seen for visual memory and recall for the group treated with vitamin E. There was no difference in attention, language or executive function between the two groups at baseline or at one year (<a href="./references#CD011492-bbs2-0001" title="ChanA , CheungMC , LawSC , ChanJH . Phase II study of alpha‐tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer January 15, 2004;100(2):398‐404. ">Chan 2004</a>). Corticosteroid requirements and adverse events to treatment were not reported in this study. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011492-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011492-sec-0091"></div> <section id="CD011492-sec-0092"> <h3 class="title" id="CD011492-sec-0092">Summary of main results</h3> <section id="CD011492-sec-0093"> <h4 class="title">Pharmacological</h4> <p>This review evaluated the effect of any pharmacological or non‐pharmacological intervention in patients with brain radionecrosis on both radiological response, clinical response and cognitive improvement. Additional secondary endpoints including dexamethasone requirements and quality of life (QoL) measures were planned for this review but there were limited data available for these endpoints within the studies included in this review. A total of 180 participants were included in the review and eligible for analysis, with one RCT contributing 137 of the 180 participants, another RCT just 14 and one non‐randomised two‐arm study evaluated 29 for the effect of pharmacological interventions. </p> <p>The two randomised studies evaluating pharmacological interventions used different drug agents, different comparison arms and different time points for response evaluation, therefore a meta‐analysis was not completed. But both drugs, edaravone and bevacizumab, were shown to result in a greater radiological response compared with their respective comparison arms of either corticosteroids or placebo, respectively. <a href="./references#CD011492-bbs2-0002" title="LevinV , BidautL , HouP , KumarA , WefelJ , BekeleB , et al. Randomized double‐blind placebo‐controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1487‐95. ">Levin 2011</a> reported a 100% radiological reduction in oedema at six weeks after starting treatment in all patients treated with bevacizumab versus clinical or radiological progression in all patients in the placebo arm. Despite this dramatic difference in response, neurocognitive function and symptom severity were largely similar between treatment arms. <a href="./references#CD011492-bbs2-0003" title="TangY , RongX , HuW , LiG , YangX , YangJ , et al. Effect of edaravone on radiation‐induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial. Journal of Neuro‐oncology 21 August 2014;120(2):441‐7. [DOI: 10.1007/s11060‐014‐1573‐4] ">Tang 2014</a> reported radiological response, defined as reduction in oedema, in 55.6% of patients treated with edaravone plus corticosteroids versus 35.4% of patients treated with corticosteroids alone. Using late effects in normal tissues subjective, objective, management and analytic scales (LENT/SOMA), patients treated with edaravone reported significant improvement in their symptoms; however, the open‐label design of this study may have impacted the results of this patient‐reported outcome. </p> <p>Neurocognitive function was evaluated in two pharmacological studies. A non‐randomised study of vitamin E versus no active treatment found that after one year of treatment, patients who received vitamin E had improvement in global cognitive function on the Cantonese version of the Mini‐Mental Status Examination (CMMSE) as well as improvement in verbal learning on the Hong Kong List Learning Tes (tHKLLT) (<a href="./references#CD011492-bbs2-0001" title="ChanA , CheungMC , LawSC , ChanJH . Phase II study of alpha‐tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer January 15, 2004;100(2):398‐404. ">Chan 2004</a>). In the randomised study of bevacizumab versus placebo, patients receiving bevacizumab also had greater improvement on learning trials and also demonstrated greater improvement in the delayed recognition trial but worsened performance on delayed free recall trial. </p> </section> <section id="CD011492-sec-0094"> <h4 class="title">Non‐pharmacological</h4> <p>No eligible studies of non‐pharmacological interventions met the eligibility criteria for this review. </p> </section> </section> <section id="CD011492-sec-0095"> <h3 class="title" id="CD011492-sec-0095">Overall completeness and applicability of evidence</h3> <p>Based on this review, although 1744 studies were retrieved through the established search criteria, after excluding reports that were unrelated to brain radionecrosis, retrospective studies, case reports or single‐arm studies, there were limited studies that prospectively evaluated the efficacy of interventions for the treatment of brain radionecrosis. A total of three prospective 2‐arm studies evaluating pharmacological interventions were identified, each evaluating a different drug agent and different endpoints. Therefore a meta‐analysis was not completed for the pharmacological interventions. There were no studies of non‐pharmacological interventions that met inclusion criteria for this review. </p> <p>Of the trials included in this review, only one study that was a double‐blinded, randomised controlled study was at low risk for any biases; however, this study had only 14 patients, of which only five patients were receiving dexamethasone at the time of study registration. A comparison of outcomes against the current standard treatment of corticosteroids would be particularly useful when considering endpoints such as patient‐reported symptoms or QoL, as corticosteroids are associated with a number of side effects (<a href="./references#CD011492-bbs2-0015" title="GiglioP , GilbertM . Cerebral radiation necrosis. Neurologist2003;9(4):180‐8. ">Giglio 2003</a>). An ongoing study entitled '<i>Corticosteroids plus bevacizumab versus corticosteroids plus placebo (BeSt) for radionecrosis after radiosurgery for brain metastases</i>' will help evaluate this clinical scenario as it is a multi‐centred randomised phase II trial of bevacizumab and steroids versus steroids and placebo in patients who are on corticosteroids for symptomatic radionecrosis following radiosurgery for brain metastases. The primary endpoint is an improvement in patient‐reported symptoms measured using the MD Anderson Symptom Inventory‐Brain Tumor (MDASI‐BT), which will reflect the effect of bevacizumab on radionecrosis symptoms as well as its associated toxicities compared with the benefit and toxicities associated with corticosteroids (<a href="./references#CD011492-bbs2-0009" title="Randomized phase II study: corticosteroids plus bevacizumab versus corticosteroids plus placebo (BeSt) for radionecrosis after radiosurgery for brain metastases. Ongoing studyApril 2016. ">A221208</a>). </p> </section> <section id="CD011492-sec-0096"> <h3 class="title" id="CD011492-sec-0096">Quality of the evidence</h3> <p>The quality of the available evidence is low to very low for all outcomes due to the limited number of prospective studies and fact only single study analyses were possible, the small number of participants in these studies, variability in the endpoints evaluated and all were at an overall high risk of bias. The trial of <a href="./references#CD011492-bbs2-0002" title="LevinV , BidautL , HouP , KumarA , WefelJ , BekeleB , et al. Randomized double‐blind placebo‐controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1487‐95. ">Levin 2011</a> was reported as a double‐blind randomised control trial but the evidence was downgraded one level for all outcomes due to the small size of 14 patients (seven patients per arm) and also downgraded one level due to lack of information regarding the randomisation and blinding procedures. All outcomes of the second RCT were downgraded one level as it was open‐label and further downgraded due to concerns regarding detection bias and inadequate blinding in the trial (<a href="./references#CD011492-bbs2-0003" title="TangY , RongX , HuW , LiG , YangX , YangJ , et al. Effect of edaravone on radiation‐induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial. Journal of Neuro‐oncology 21 August 2014;120(2):441‐7. [DOI: 10.1007/s11060‐014‐1573‐4] ">Tang 2014</a>). One two‐arm non‐randomised study was at risk of selection bias and performance bias because participants were able to choose the treatment arm (<a href="./references#CD011492-bbs2-0001" title="ChanA , CheungMC , LawSC , ChanJH . Phase II study of alpha‐tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer January 15, 2004;100(2):398‐404. ">Chan 2004</a>) and thus the quality of the evidence for all reported outcomes was very low ('Summary of findings' table therefore not completed since this is not an RCT and in fact we do not want to emphasise study results in a main section of the review). The quality of evidence for treatment‐related severe adverse events was low for bevacizumab due to the small size of the trial (<a href="./references#CD011492-bbs2-0002" title="LevinV , BidautL , HouP , KumarA , WefelJ , BekeleB , et al. Randomized double‐blind placebo‐controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1487‐95. ">Levin 2011</a>), and also low for the edaravone plus corticosteroid trial due to the open‐label design of the trial that may have impacted the selection of participants who received edaravone (<a href="./references#CD011492-bbs2-0003" title="TangY , RongX , HuW , LiG , YangX , YangJ , et al. Effect of edaravone on radiation‐induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial. Journal of Neuro‐oncology 21 August 2014;120(2):441‐7. [DOI: 10.1007/s11060‐014‐1573‐4] ">Tang 2014</a>). None of the included studies reported quality of life outcomes or adequately reported details about corticosteroid requirements so quality of the evidence for these outcomes was very low. </p> <p>Based on the overall low to very low‐certainty of evidence, further research is very likely to have an important impact on our confidence in the estimate of effect of each treatment. </p> </section> <section id="CD011492-sec-0097"> <h3 class="title" id="CD011492-sec-0097">Potential biases in the review process</h3> <p>An extensive search through the listed databases including published studies and conference proceedings, as well as publications listed in the references of review articles was completed for this review, which minimised the risk of missing any eligible studies. We were unable to acquire additional information beyond the published data for the included studies, which limited our ability to report all studies as per the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011492-bbs2-0017" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Chichester: John Wiley &amp; Sons, 2011. ">Higgins 2011</a>). </p> </section> <section id="CD011492-sec-0098"> <h3 class="title" id="CD011492-sec-0098">Agreements and disagreements with other studies or reviews</h3> <section id="CD011492-sec-0099"> <h4 class="title">Corticosteroids</h4> <p>For patients with symptomatic brain radionecrosis, corticosteroids are typically the first‐line treatment, as they effectively reduce symptoms associated with brain oedema and also inhibit the pro‐inflammatory processes involved in radionecrosis (<a href="./references#CD011492-bbs2-0015" title="GiglioP , GilbertM . Cerebral radiation necrosis. Neurologist2003;9(4):180‐8. ">Giglio 2003</a>). However, withdrawal of corticosteroids may result in a rebound of the oedema and related symptoms and prolonged use of corticosteroids can be associated with significant toxicity including steroid myopathy, iatrogenic Cushing's syndrome and glucose intolerance (<a href="./references#CD011492-bbs2-0015" title="GiglioP , GilbertM . Cerebral radiation necrosis. Neurologist2003;9(4):180‐8. ">Giglio 2003</a>). </p> </section> <section id="CD011492-sec-0100"> <h4 class="title">Bevacizumab</h4> <p>There have been several recent reviews addressing the use of bevacizumab for brain radionecrosis (<a href="./references#CD011492-bbs2-0034" title="TyeK , EngelhardHH , SlavinKV , NicholasMK , ChmuraSJ , KwokY , et al. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. Journal of Neuro‐oncology2014;117(2):321‐7. ">Tye 2014</a>; <a href="./references#CD011492-bbs2-0021" title="LubelskiD , AbdullahKG , WeilRJ , MarkoNF . Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature. Journal of Neuro‐oncology2013;115(3):317‐22. ">Lubelski 2013</a>) that included data from both retrospective and prospective studies. <a href="./references#CD011492-bbs2-0021" title="LubelskiD , AbdullahKG , WeilRJ , MarkoNF . Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature. Journal of Neuro‐oncology2013;115(3):317‐22. ">Lubelski 2013</a> reported on 30 patients included in seven studies of bevacizumab for patients with brain radionecrosis following treatment for high‐grade glioma. Similar to this review, all patients demonstrated a radiographic response on T1 and T2‐weighted magnetic resonance imaging (MRI). Out of the 23 patients for which clinical data were reported, 16 (70%) showed an improvement in this study (<a href="./references#CD011492-bbs2-0021" title="LubelskiD , AbdullahKG , WeilRJ , MarkoNF . Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature. Journal of Neuro‐oncology2013;115(3):317‐22. ">Lubelski 2013</a>). A subsequent broader review that included 71 patients treated with bevacizumab for brain radionecrosis after treatment of any brain tumour across 16 studies reported radiographic improvement in 97% of patients and improvement in performance status in 79% of patients. (<a href="./references#CD011492-bbs2-0034" title="TyeK , EngelhardHH , SlavinKV , NicholasMK , ChmuraSJ , KwokY , et al. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. Journal of Neuro‐oncology2014;117(2):321‐7. ">Tye 2014</a>) Therefore, these prior reviews are in agreement with the current systematic review that the radiographic response rate to bevacizumab is high for patients with brain radionecrosis and this response may be associated with symptomatic or functional improvement. </p> </section> <section id="CD011492-sec-0101"> <h4 class="title">Pentoxifylline and vitamin E</h4> <p>Pentoxifylline (PTX) is a methylxanthine derivative that decreases blood viscosity thereby increasing blood circulation and tissue oxygenation. Vitamin E (or tocopherol) acts as a free‐radical scavenger. In a small retrospective study of 11 patients with brain radionecrosis following radiotherapy for brain metastases, meningioma and arteriovenous malformations (AVM), the combination of PTX and vitamin E resulted in radiological improvement in all but one patient, who was eventually confirmed to have tumour recurrence (<a href="./references#CD011492-bbs2-0035" title="WilliamsonR , KondziolkaD , KanaanH , LunsfordLD , FlickingerJC . Adverse radiation effects after radiosurgery may benefit from oral vitamin E and pentoxifylline therapy: a pilot study. Stereotactic Functional Neurosurgery2008;86(6):359‐66. ">Williamson 2008</a>). Although the prospective trial included in the current systematic review evaluated the cognitive impact of vitamin E alone and reported greater improvement on cognitive testing at one year of treatment, this prospective trial did not report on radiological response. </p> </section> <section id="CD011492-sec-0102"> <h4 class="title">Hyperbaric oxygen (HBO) therapy</h4> <p>There are limited small retrospective case reports and case studies reporting the outcomes of HBO therapy for brain radionecrosis. <a href="./references#CD011492-bbs2-0026" title="PasquierD , HoelscherT , SchmutzJ , SchmutzJ , DischeS , MathieuD , et al. Hyperbaric oxygen therapy in the treatment of radio‐induced lesions in normal tissues: a literature review. Radiotherapy and Oncology2004;72(1):1‐13. ">Pasquier 2004</a> reported limited retrospective reports of HBO therapy for brain radionecrosis as part of a larger review of HBO therapy for radiation injury to all body sites. These retrospective reports suggested promising responses to HBO therapy to some patients, however no prospective data are available to‐date. A trial entitled "Adverse radiation effects after Gamma Knife radio surgery and Hyperbaric Oxygen Therapy (GKSHBO)" was activated in March 2016. This is a single‐arm study evaluating the impact of (HBO on clinical improvement and reduction of oedema in patients who develop cerebral radiation necrosis following gamma knife radiosurgery (GKS) (<a href="./references#CD011492-bbs2-0010" title="Treatment of adverse radiation effects after gamma knife radiosurgery (GKS) and hyperbaric oxygen therapy (HBO). Ongoing studyMarch 2016. ">NCT02714465</a>). </p> </section> <section id="CD011492-sec-0103"> <h4 class="title">Surgery</h4> <p>Although surgery is frequently used in clinical practice to address progressive resectable radionecrosis lesions, no prospective trials of surgical resection for brain radionecrosis were identified in this review. A retrospective series of 24 adult patients who underwent craniotomy and resection of contrast‐enhancing lesions in the temporal lobes (16 unilateral; 8 bilateral) following radiotherapy for nasopharyngeal carcinoma reported a reduction in the extent of brain oedema observed on either computed tomography (CT) or MRI in the 15 patients who had serial imaging. Only one patient required a repeat resection for recurrent necrosis (<a href="./references#CD011492-bbs2-0037" title="WongST , LooKT , YamKY , HungWM , FokKF , YuenSC , et al. Results of excision of cerebral radionecrosis: experience in patients treated with radiation therapy for nasopharyngeal carcinoma. Journal of Neuro‐oncology2010;113(2):293‐300. ">Wong 2010</a>). In patients who were treated with radiosurgery, a retrospective series of 15 patients treated with surgical resection for radionecrosis reported improvement in brain oedema resulting in either a partial or complete taper off corticosteroids as well as symptom improvement in the majority of patients (<a href="./references#CD011492-bbs2-0032" title="TeleraS , FabiA , PaceA , VidiriA , AnelliV , CarapellaCM , et al. Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease. Journal of Neuro‐oncology2013;113(2):313‐25. ">Telera 2013</a>). </p> </section> <section id="CD011492-sec-0104"> <h4 class="title">Laser‐induced thermal therapy (LITT)</h4> <p>Only one single‐arm study of a LITT, a non‐pharmacological intervention, was identified in the search, but this study did not meet eligibility criteria. This single‐arm study of LITT reported promising local control of 75.8% (13 of 15 lesions), and dramatic reductions in lesion volume to less than 10% of the pre‐treated volume in seven of the treated lesions (<a href="./references#CD011492-bbs2-0005" title="RaoMS , HargreavesEL , KhanAJ , HafftyBG , DanishSF . Magnetic resonance‐guided laser ablation improves local control for postradiosurgery recurrenceand/or radiation necrosis. Neurosurgery2014;74(6):658‐67. ">Rao 2014</a>). However, as this was a single‐arm study with a limited number of patients, further prospective investigation is required to compare the effect of this treatment against current management approaches. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011492-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011492-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011492-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus placebo, Outcome 1 Change in HVLT‐R Total Recall." data-id="CD011492-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus placebo, Outcome 1 Change in HVLT‐R Total Recall.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus placebo, Outcome 2 Change in HVLT‐R Delayed Recall." data-id="CD011492-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus placebo, Outcome 2 Change in HVLT‐R Delayed Recall.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus placebo, Outcome 3 Change in HVLT‐R Delayed Recognition." data-id="CD011492-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus placebo, Outcome 3 Change in HVLT‐R Delayed Recognition.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus placebo, Outcome 4 Change in TMTA." data-id="CD011492-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus placebo, Outcome 4 Change in TMTA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus placebo, Outcome 5 Change in TMTB." data-id="CD011492-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus placebo, Outcome 5 Change in TMTB.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus placebo, Outcome 6 Change in COWA." data-id="CD011492-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus placebo, Outcome 6 Change in COWA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus placebo, Outcome 7 Change in MDASI‐Severity." data-id="CD011492-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus placebo, Outcome 7 Change in MDASI‐Severity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus placebo, Outcome 8 Change in NCF6Z." data-id="CD011492-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus placebo, Outcome 8 Change in NCF6Z.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Edaravone plus corticosteroids versus corticosteroids (CS), Outcome 1 Reduction in T2 hyperintensity." data-id="CD011492-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Edaravone plus corticosteroids versus corticosteroids (CS), Outcome 1 Reduction in T2 hyperintensity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Edaravone plus corticosteroids versus corticosteroids (CS), Outcome 2 Reduction in post‐gadolinium enhancement." data-id="CD011492-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Edaravone plus corticosteroids versus corticosteroids (CS), Outcome 2 Reduction in post‐gadolinium enhancement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011492-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/urn:x-wiley:14651858:media:CD011492:CD011492-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_t/tCD011492-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Edaravone plus corticosteroids versus corticosteroids (CS), Outcome 3 Improvement in LENT/SOMA scale." data-id="CD011492-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Edaravone plus corticosteroids versus corticosteroids (CS), Outcome 3 Improvement in LENT/SOMA scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/media/CDSR/CD011492/image_n/nCD011492-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011492-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Bevacizumab compared to placebo for the treatment of brain radionecrosis after radiotherapy or radiosurgery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Bevacizumab compared to placebo for the treatment of brain radionecrosis after radiotherapy or radiosurgery</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain radionecrosis based on clinical and radiological criteria<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> bevacizumab<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Summary</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in oedema (T2 hyperintensity)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very small sample size so results were reported descriptively. At 6 weeks, all seven (100%) participants on bevacizumab had a reduction in brain oedema by at least 25%, whereas 0/7 participants receiving placebo had this reduction. All participants in the placebo arm had clinical and/or radiological progression. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported due to sparse data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in post‐gadolinium enhancement</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very small sample size so results were reported descriptively. Very small sample size so results were reported descriptively. At 6 weeks, all seven (100%) participants on bevacizumab had a reduction in post‐gadolinium enhancement, whereas 0/7 participants receiving placebo had this reduction. All participants in the placebo arm had clinical and/or radiological progression. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported due to sparse data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in neurological/clinical symptoms/severity<br/> <br/> Follow‐up: range 6 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 or 7 who received bevacizumab had stable or reduced clinical symptoms versus only 2 of 7 who received placebo. 5 of 7 patients had worsening neurological symptoms at 3.1 to 8.8 weeks after the first dose of placebo. </p> <p>Since there appeared to be no differences in neurocognitive test results in the trial versus cross‐over bevacizumab treated participant combined, all bevacizumab participants were pooled into one group. While the validity of this is questionable, no significant differences in neurocognitive function changes or symptom severity were observed with bevacizumab treatment compared with placebo in any of the analyses </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported due to sparse data and validity concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No Severe adverse events in 7/7 placebo patients. 3/11 patients who received bevacizumab had severe adverse events (although this overlapped with cross‐over patients). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="2" valign=""> <p>None of the included studies reported quality of life outcomes or adequately reported details about corticosteroid requirements </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corticosteroid requirements</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to small sample size </p> <p><sup>2</sup> Lack of information regarding the randomisation and blinding procedures and overall high risk of bias </p> <p>3 Concerns over validity of analyses</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Bevacizumab compared to placebo for the treatment of brain radionecrosis after radiotherapy or radiosurgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011492-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Edaravone plus corticosteroids compared to corticosteroids for the treatment of brain radionecrosis after radiotherapy or radiosurgery</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Edaravone plus corticosteroids compared to corticosteroids for the treatment of brain radionecrosis after radiotherapy or radiosurgery</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain radionecrosis based on clinical and radiological criteria<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> edaravone + corticosteroids<br/> <b>Comparison:</b> corticosteroids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Summary</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in oedema (T2 hyperintensity)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>At 3 months after completing study treatment, greater reduction in brain oedema (5.08 ± 10.32 cm<sup>2</sup>) was noted in the edaravone + corticosteroid group (edaravone 30 mg orally twice daily for 14 days plus conventional methylprednisolone 500 mg IV x 3 days followed by tapering prednisone orally) than in the corticosteroid alone group (2.05 ± 6.71 cm<sup>2</sup>) although the result approached borderline significance (P = 0.04) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD = 3.03, 95% CI 0.14 to 5.92</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in post‐gadolinium enhancement</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>At 3 months after completing study treatment, there was no evidence of any important difference in the reduction in post‐gadolinium enhancement between arms (1.67 ± 4.69 cm<sup>2</sup>; control group, 1.20 ± 2.71 cm<sup>2</sup>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD = 0.47, 95% CI ‐0.80 to 1.74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in LENT/SOMA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>At 3 months after completing study treatment, participants who received the combination treatment were noted to have significantly greater clinical improvement than corticosteroids alone measured using the Late Effects Normal Tissue Task Force‐Subjective, Objective, Management, Analytic (LENT‐SOMA) scale and defining improvement as a reduction in the LENT‐SOMA scale of &gt; 1. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR = 2.51, 95% CI 1.26 to 5.01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> LOW <sup>1 2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in neurocognitive function</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No differences in treatment toxicities were observed between arms and no severe adverse events were reported. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="2" valign=""> <p>None of the included studies reported quality of life outcomes or adequately reported details about corticosteroid requirements </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corticosteroid requirements</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup> Open‐label trial </p> <p><sup>2</sup> At overall high risk of bias and/or imprecision in estimate </p> <p><sup>3</sup> Inadequate blinding giving high risk of detection bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Edaravone plus corticosteroids compared to corticosteroids for the treatment of brain radionecrosis after radiotherapy or radiosurgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/full#CD011492-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011492-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bevacizumab versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in HVLT‐R Total Recall <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in HVLT‐R Delayed Recall <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in HVLT‐R Delayed Recognition <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change in TMTA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change in TMTB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change in COWA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in MDASI‐Severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change in NCF6Z <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bevacizumab versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011492-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Edaravone plus corticosteroids versus corticosteroids (CS)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Reduction in T2 hyperintensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Reduction in post‐gadolinium enhancement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Improvement in LENT/SOMA scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Edaravone plus corticosteroids versus corticosteroids (CS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011492.pub2/references#CD011492-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011492.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011492-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011492-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011492-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011492-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011492-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011492-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011492\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011492\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011492\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011492\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011492\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011492.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011492.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011492.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011492.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011492.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719083584"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011492.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719083588"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011492.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de01a4b731be4',t:'MTc0MDcxOTA4My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 